Table 2.
Comparison of 18F-FDG and 68Ga-MY6349 uptake in primary and metastatic breast cancer
| Tumor location | 18F-FDG PET/CT | 68Ga-MY6349 PET/CT | P1 | |||
|---|---|---|---|---|---|---|
| SUVmax, median (Q1-Q3) | TBR, median (Q1-Q3) | SUVmax, median (Q1-Q3) | TBR, median (Q1-Q3) | SUVmax (MY6349 vs. FDG) |
TBR (MY6349 vs. FDG) |
|
| Breast lesions | 4.1 (2.7–7.3) | 2.9 (1.3–4.8) | 4.9 (3.8–7.2) | 6.6 (3.3–11.2) | 0.163 | < 0.001 |
| Local/distant lymph node metastases | 4.2 (2.4–7.0) | 5.3 (3.0–9.6) | 5.6 (3.5–8.1) | 7.8 (4.5–12.9) | 0.002 | < 0.001 |
| Bone and visceral metastases | 4.0 (2.6–6.8) | 3.0 (1.8–5.2) | 6.3 (3.6–8.8) | 5.0 (2.6–7.1) | < 0.001 | < 0.001 |
| Brain metastases | 15.3 (10.2–18.3) | 1.0 (0.8–1.0) | 8.5 (5.8–12.2) | 6.1 (4.3–23.7) | 0.063 | 0.018 |
| Uncommon metastases2 | 3.8 (2.1–8.1) | 3.4 (1.6–6.5) | 6.4 (2.9–9.0) | 6.3 (3.8–7.9) | 0.268 | 0.046 |
| Total | 4.1 (2.5–7.2) | 3.4 (2.1–6.7) | 5.9 (3.6–8.6) | 6.0 (3.6–9.6) | < 0.001 | < 0.001 |
CT: computed tomography; PET: positron emission tomography; FDG: fluorodeoxyglucose; Q: quartile; SUVmax: maximum standardized uptake value; TBR: tumor-to-background ratio.
1: Wilcoxon signed-rank test.
2: Uncommon metastases include muscular, subcutaneous, gingival, ovarian, pleural and mesenteric metastases.